Ranbaxy Pharmaceuticals, Canada (RPCI), a wholly-owned subsidiary of Ranbaxy Laboratories, and Janssen-Ortho (JOI), have entered into a licensing and supply agreement for a generic fentanyl patch.According to a release issued by Ranbaxy to the BSE, the patch is sold under its trademark as Ran Fentanyl Transdermal System."Ran Fentanyl Transdermal System is classified as an opioid analgesic drug, and is indicated for the management of persistent, moderate to severe chronic pain.Bill Abboud, president and GM of RPCI, said: "This agreement, which also includes Risperidone, will provide Ranbaxy with an opportunity to commercialise products that continue to have a favorable impact on the Canadian healthcare system."
